Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News April 22nd 2011

April 22nd 2011

Diabetes in adults quality standard
This NICE quality standard defines clinical best practice within this topic area. It provides specific, concise quality statements, measures and audience descriptors to provide patients and the public, health and social care professionals, commissioners and service providers with definitions of high-quality care – Full PDF (NICE)

Artificial pancreas promise for night-time hypos
Research funded by Diabetes UK, and supported by the Juvenile Diabetes Resarch Foundation (JDRF), has for the first time successfully demonstrated the potential of an ‘artificial pancreas’ in preventing night-time hypoglycaemia in adults with Type 1 diabetes (Diabetes UK)

The utility of hemoglobin A1c at diagnosis for prediction of future glycemic control in children with type 1 diabetes
In children with newly diagnosed diabetes, A1cs at diagnosis and one year post diagnosis are related to subsequent glycemic control. Children with high A1cs particularly at one year post diagnosis may benefit from targeted intensification of resources (Diabetes Research and Clinical Practice)

The Cost-Effectiveness of Three Screening Alternatives for People with Diabetes with No or Early Diabetic Retinopathy
Annual eye evaluations are costly and add little benefit compared with either plausible alternative. More research on the ability of telemedicine to detect other eye conditions is needed to determine whether it is more cost-effective than biennial eye evaluation (Health Services Research)

BYDUREON™ Recommended for Approval in Europe
BYDUREON Would Be First Once-Weekly Treatment for Adults with Type 2 Diabetes (Lilly)

Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
A 6-week treatment with ezetimibe and simvastatin, compared to simvastatin alone, positively influences lipoprotein profile both at fasting and postprandially in type 2 diabetic patients by favouring the production of cholesterol-poor chylomicrons and VLDL particles that have less atherogenic potential (PubMed)

Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug
San Diego-based Amylin, along with Lilly and Waltham, MA-based Alkermes, said that their once-weekly version of exenatide (Bydureon) received a recommendation for approval in Europe (Xconomy San Diego)

Mobile phone intervention improves glycemic control in type 2 diabetes patients
The results of the analysis indicate that the innovative use of mobile phone interventions in the self-management of diabetes significantly improve glycemic control especially in individuals with type 2 diabetes (Diabetes Pro)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskSanofi DiabetesAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership